Bulimia Nervosa Market Research Report - Global Forecast till 2025

Global Bulimia Nervosa Market Research Report: Information by Disorder Type (Purging and Non-Purging), Drug Type (Antidepressants, Antipsychotics, and Others), Route of Administration (Oral, Intravenous, and Others), End User (Hospitals & Clinics, Homecare Settings, Specialty Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2025

ID: MRFR/Pharma/0908-HCR | February 2021 | Region: Global | 85 pages

 
Market Scenario
The global bulimia nervosa market is expected to exhibit significant growth over the forecast period. The market was valued at approximately USD 429.84 million in 2018 and is projected to register a 4.9% CAGR over the forecast period.
Bulimia nervosa is an eating disorder that is characterized by eating a large amount of food (binge eating) in a short period. The disorder is also known as bulimia. Bulimia nervosa may cause various life-threatening and serious complications, such as heart problems, tooth & gum decay, anxiety, self-injury, dehydration, and digestive problems.
Factors such as the rising prevalence of psychological disorders, alcoholism, and diabetes are expected to drive market growth. According to an article published by the National Alliance on Mental Illness (NAMI), 19.1% adults in the US experienced mental illness in 2018. Moreover, drastically changing lifestyle is also expected to boost market growth.
However, factors such as the lack of drugs specifically for the treatment of bulimia nervosa and lack of awareness regarding the treatment options are expected to hamper the market growth. 
 
Segmentation
The global bulimia nervosa market has been segmented into disorder type, drug type, route of administration, end user, and region.
Based on disorder type, the global bulimia nervosa market has been divided into purging and non-purging.
The global bulimia nervosa market, by drug type, has been segmented into antidepressants, antipsychotics, and others.
Based on route of administration, the global bulimia nervosa market is segmented into oral, intravenous, and others.
The global bulimia nervosa market, by end user, has been segmented into hospitals & clinics, home care settings, specialty centers, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The bulimia nervosa market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European bulimia nervosa market has been segmented into Western Europe and Eastern Europe. The market in Western Europe has further been classified as France, Germany, Spain, the UK, Italy, and the rest of Western Europe. 
The bulimia nervosa market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The Middle East & Africa bulimia nervosa market is segmented into the Middle East and Africa.  
 
Key Players
Allergan, Inc. (Ireland), Eli Lilly and Company (US), AstraZeneca (UK), Bristol-Myers Squibb Company (US), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Johnson & Johnson Services, Inc. (US), Dr. Reddy’s Laboratories Limited (India), Lupin Pharmaceuticals, Inc. (India), Aurobindo Pharma (India), Zydus Cadila (India), Apotex Inc. (Canada), Teva Pharmaceutical Industries Ltd (Israel) and Sun Pharmaceutical Industries Ltd (India) are some of the key players operating in the global bulimia nervosa market.
 
Regional Market Summary
 
Global Bulimia Nervosa Market Share (%), by Region, 2018

Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, and Annual Reports
Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is anticipated to dominate the global bulimia nervosa market owing to the rising prevalence of bulimia nervosa. According to data published by the National Institute of Mental Health (NIMH) in November 2017, 43.2% people suffering from bulimia nervosa sought treatment for their disorder in the US.
Europe is expected to hold the second-largest share of the global bulimia nervosa market owing to the presence of major market players such as AstraZeneca and GlaxoSmithKline plc.
Asia-Pacific is expected to be the fastest-growing regional market owing to the rising awareness regarding mental disorders and high incidence rate of bulimia nervosa.
The bulimia nervosa market in the Middle East & Africa is expected to hold the least share during the forecast period.
 
Global Bulimia Nervosa Market, by Disorder Type


  • Purging

  • Non-Purging


Global Bulimia Nervosa Market, by Drug Type

  • Antidepressants

  • Antipsychotics

  • Others


Global Bulimia Nervosa Market, by Route of Administration

  • Oral

  • Intravenous

  • Others


Global Bulimia Nervosa Market, by End User

  • Hospitals and Clinics

  • Homecare Settings

  • Specialty Centers

  • Others


Global Bulimia Nervosa Market, by Region

  • Americas

    • North America

    • US

    • Canada

    • Latin America





  • Europe

    • Western Europe

    • Germany

    • France

    • Italy

    • Spain

    • UK

    • Rest of Western Europe

    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience

  • Biotechnology companies

  • Research institutes

  • Pharmaceutical companies

  • Hospitals and clinics

  • Ambulatory surgical centers

  • Academic institutes

  • Government organizations



Table of Contents


1. REPORT PROLOGUE


2. MARKET INTRODUCTION


2.1. Definition


2.2. Scope of the Study


2.2.1. Research Objective


2.2.2. Assumptions


2.2.3. Limitations


3. RESEARCH METHODOLOGY


3.1. Overview


3.2. Primary Research


3.3. Secondary Research


3.4. Market Size Estimation


4. MARKET DYNAMICS


4.1. Overview


4.2. Drivers


4.3. Restraints


4.4. Opportunities


5. MARKET FACTOR ANALYSIS


5.1. Porter’s Five Forces Analysis


5.1.1. Bargaining Power of Suppliers


5.1.2. Bargaining Power of Buyers


5.1.3. Threat of New Entrants


5.1.4. Threat of Substitutes


5.1.5. Intensity of Rivalry


5.2. Value Chain Analysis




6. GLOBAL BULIMIA NERVOSA MARKET, BY DISORDER TYPE


6.1. Overview


6.2. Purging


Market Estimates & Forecast, by Region, 2019–2025


Market Estimates & Forecast, by Country, 2019–2025


6.3. Non-Purging


Market Estimates & Forecast, by Region, 2019–2025


Market Estimates & Forecast, by Country, 2019–2025


7. GLOBAL BULIMIA NERVOSA MARKET, BY DRUG TYPE


7.1. Overview


7.2. Antidepressants


Market Estimates & Forecast, by Region, 2019–2025


Market Estimates & Forecast, by Country, 2019–2025


7.3. Antipsychotics


Market Estimates & Forecast, by Region, 2019–2025


Market Estimates & Forecast, by Country, 2019–2025


7.4. Others


Market Estimates & Forecast, by Region, 2019–2025


Market Estimates & Forecast, by Country, 2019–2025


8. GLOBAL BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION


8.1. Overview


8.2. Oral


Market Estimates & Forecast, by Region, 2019–2025


Market Estimates & Forecast, by Country, 2019–2025


8.3. Intravenous


Market Estimates & Forecast, by Region, 2019–2025


Market Estimates & Forecast, by Country, 2019–2025


8.4. Others


Market Estimates & Forecast, by Region, 2019–2025


Market Estimates & Forecast, by Country, 2019–2025


9. GLOBAL BULIMIA NERVOSA MARKET, BY END USER


9.1. Overview


9.2. Hospitals & Clinics


Market Estimates & Forecast, by Region, 2019–2025


Market Estimates & Forecast, by Country, 2019–2025


9.3. Homecare Settings


Market Estimates & Forecast, by Region, 2019–2025


Market Estimates & Forecast, by Country, 2019–2025


9.4. Specialty Centers


Market Estimates & Forecast, by Region, 2019–2025


Market Estimates & Forecast, by Country, 2019–2025


9.5. Others


Market Estimates & Forecast, by Region, 2019–2025


Market Estimates & Forecast, by Country, 2019–2025


10. GLOBAL BULIMIA NERVOSA MARKET, BY REGION


10.1. Overview


10.2. Americas


10.2.1. North America


10.2.1.1. US


10.2.1.2. Canada


10.2.2. Latin America


10.3. Europe


10.3.1. Western Europe


10.3.1.1. Germany


10.3.1.2. France


10.3.1.3. Italy


10.3.1.4. Spain


10.3.1.5. UK


10.3.1.6. Rest of Western Europe


10.3.2. Eastern Europe


10.4. Asia-Pacific


10.4.1. Japan


10.4.2. China


10.4.3. India


10.4.4. Australia


10.4.5. South Korea


10.4.6. Rest of Asia-Pacific


10.5. Middle East & Africa


10.5.1. Middle East


10.5.2. Africa


11. COMPANY LANDSCAPE


11.1. Overview


11.2. Competitive Analysis


11.3. Market Share Analysis


11.4. Major Growth Strategies in the Global Bulimia Nervosa Market


11.5. Competitive Benchmarking


11.6. Leading Players in Terms of Number of Developments in the Global Bulimia Nervosa Market


11.7. Key Developments and Growth Strategies


11.7.1. Product Launch/Service Deployment


11.7.2. Mergers and Acquisitions


11.7.3. Joint Ventures


11.8. Major Players Financial Matrix & Market Ratio


11.8.1. Sales & Operating Income 2018


11.8.2. Major Players R&D Expenditure 2018


11.9. Major Players Capital Market Ratio


12. COMPANY PROFILES


12.1. Allergan, Inc.


12.1.1. Company Overview


12.1.2. Product Overview


12.1.3. Financial Overview


12.1.4. Key Developments


12.1.5. SWOT Analysis


12.1.6. Key Strategies


12.2. Eli Lilly and Company


12.2.1. Company Overview


12.2.2. Product Overview


12.2.3. Financial Overview


12.2.4. Key Developments


12.2.5. SWOT Analysis


12.2.6. Key Strategies


12.3. AstraZeneca


12.3.1. Company Overview


12.3.2. Product Overview


12.3.3. Financial Overview


12.3.4. Key Developments


12.3.5. SWOT Analysis


12.3.6. Key Strategies


12.4. Bristol-Myers Squibb Company


12.4.1. Company Overview


12.4.2. Product Overview


12.4.3. Financial Overview


12.4.4. Key Developments


12.4.5. SWOT Analysis


12.4.6. Key Strategies


12.5. GlaxoSmithKline plc


12.5.1. Company Overview


12.5.2. Product Overview


12.5.3. Financial Overview


12.5.4. Key Developments


12.5.5. SWOT Analysis


12.5.6. Key Strategies


12.6. Pfizer Inc.


12.6.1. Company Overview


12.6.2. Product Overview


12.6.3. Financial Overview


12.6.4. Key Developments


12.6.5. SWOT Analysis


12.6.6. Key Strategies


12.7. Johnson & Johnson Services, Inc.


12.7.1. Company Overview


12.7.2. Product Overview


12.7.3. Financial Overview


12.7.4. Key Developments


12.7.5. SWOT Analysis


12.7.6. Key Strategies


12.8. Dr. Reddy’s Laboratories Limited


12.8.1. Company Overview


12.8.2. Product Overview


12.8.3. Financial Overview


12.8.4. Key Developments


12.8.5. SWOT Analysis


12.8.6. Key Strategies


12.9. Lupin Pharmaceuticals, Inc.


12.9.1. Company Overview


12.9.2. Product Overview


12.9.3. Financial Overview


12.9.4. Key Developments


12.9.5. SWOT Analysis


12.9.6. Key Strategies


12.10. Aurobindo Pharma


12.10.1. Company Overview


12.10.2. Product Overview


12.10.3. Financial Overview


12.10.4. Key Developments


12.10.5. SWOT Analysis


12.10.6. Key Strategies


12.11. Zydus Cadila


12.11.1. Company Overview


12.11.2. Product Overview


12.11.3. Financial Overview


12.11.4. Key Developments


12.11.5. SWOT Analysis


12.11.6. Key Strategies


12.12. Apotex Inc.


12.12.1. Company Overview


12.12.2. Product Overview


12.12.3. Financial Overview


12.12.4. Key Developments


12.12.5. SWOT Analysis


12.12.6. Key Strategies


12.13. Teva Pharmaceutical Industries Ltd


12.13.1. Company Overview


12.13.2. Product Overview


12.13.3. Financial Overview


12.13.4. Key Developments


12.13.5. SWOT Analysis


12.13.6. Key Strategies


12.14. Sun Pharmaceutical Industries Ltd


12.14.1. Company Overview


12.14.2. Product Overview


12.14.3. Financial Overview


12.14.4. Key Developments


12.14.5. SWOT Analysis


12.14.6. Key Strategies


12.15. Others


13. APPENDIX


13.1. References


13.2. Related Reports




LIST OF TABLES


TABLE 1 GLOBAL BULIMIA NERVOSA MARKET SYNOPSIS, 2019–2025


TABLE 2 GLOBAL BULIMIA NERVOSA MARKET ESTIMATES & FORECAST, 2019–2025 (USD MILLION)


TABLE 3 GLOBAL BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2019–2025 (USD MILLION)


TABLE 4 GLOBAL BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)


TABLE 5 GLOBAL BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)


TABLE 6 GLOBAL BULIMIA NERVOSA MARKET, BY END USER, 2019–2025 (USD MILLION)


TABLE 7 GLOBAL BULIMIA NERVOSA MARKET, BY REGION, 2019–2025 (USD MILLION)


TABLE 8 NORTH AMERICA: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2019–2025 (USD MILLION)


TABLE 9 NORTH AMERICA: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)


TABLE 10 NORTH AMERICA: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)


TABLE 11 NORTH AMERICA: BULIMIA NERVOSA MARKET, BY END USER, 2019–2025 (USD MILLION)


TABLE 12 US: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2019–2025 (USD MILLION)


TABLE 13 US: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)


TABLE 14 US: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)


TABLE 15 US: BULIMIA NERVOSA MARKET, BY END USER, 2019–2025 (USD MILLION)


TABLE 16 CANADA: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2019–2025 (USD MILLION)


TABLE 17 CANADA: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)


TABLE 18 CANADA: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)


TABLE 19 CANADA: BULIMIA NERVOSA MARKET, BY END USER, 2019–2025 (USD MILLION)


TABLE 20 LATIN AMERICA: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2019–2025 (USD MILLION)


TABLE 21 LATIN AMERICA: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)


TABLE 22 LATIN AMERICA: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)


TABLE 23 LATIN AMERICA: BULIMIA NERVOSA MARKET, BY END USER, 2019–2025 (USD MILLION)


TABLE 24 EUROPE: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2019–2025 (USD MILLION)


TABLE 25 EUROPE: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)


TABLE 26 EUROPE: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)


TABLE 27 EUROPE: BULIMIA NERVOSA MARKET, BY END USER, 2019–2025 (USD MILLION)


TABLE 28 WESTERN EUROPE: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2019–2025 (USD MILLION)


TABLE 29 WESTERN EUROPE: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)


TABLE 30 WESTERN EUROPE: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)


TABLE 31 WESTERN EUROPE: BULIMIA NERVOSA MARKET, BY END USER, 2019–2025 (USD MILLION)


TABLE 32 EASTERN EUROPE: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2019–2025 (USD MILLION)


TABLE 33 EASTERN EUROPE: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)


TABLE 34 EASTERN EUROPE: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)


TABLE 35 EASTERN EUROPE: BULIMIA NERVOSA MARKET, BY END USER, 2019–2025 (USD MILLION)


TABLE 36 ASIA-PACIFIC: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2019–2025 (USD MILLION)


TABLE 37 ASIA-PACIFIC: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)


TABLE 38 ASIA-PACIFIC: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)


TABLE 39 ASIA-PACIFIC: BULIMIA NERVOSA MARKET, BY END USER, 2019–2025 (USD MILLION)


TABLE 40 MIDDLE EAST & AFRICA: BULIMIA NERVOSA MARKET, BY DISORDER TYPE, 2019–2025 (USD MILLION)


TABLE 41 MIDDLE EAST & AFRICA: BULIMIA NERVOSA MARKET, BY DRUG TYPE, 2019–2025 (USD MILLION)


TABLE 42 MIDDLE EAST & AFRICA: BULIMIA NERVOSA MARKET, BY ROUTE OF ADMINISTRATION, 2019–2025 (USD MILLION)


TABLE 43 MIDDLE EAST & AFRICA: BULIMIA NERVOSA MARKET, BY END USER, 2019–2025 (USD MILLION)




LIST OF FIGURES


FIGURE 1 RESEARCH PROCESS


FIGURE 2 MARKET STRUCTURE OF THE GLOBAL BULIMIA NERVOSA MARKET


FIGURE 3 MARKET DYNAMICS OF THE GLOBAL BULIMIA NERVOSA MARKET


FIGURE 4 GLOBAL BULIMIA NERVOSA MARKET SHARE, BY DISORDER TYPE, 2018 (%)


FIGURE 5 GLOBAL BULIMIA NERVOSA MARKET SHARE, BY DRUG TYPE, 2018 (%)


FIGURE 6 GLOBAL BULIMIA NERVOSA MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2018 (%)


FIGURE 7 GLOBAL BULIMIA NERVOSA MARKET SHARE, BY END USER, 2018 (%)


FIGURE 8 GLOBAL BULIMIA NERVOSA MARKET SHARE, BY REGION, 2018 (%)


FIGURE 7 AMERICAS: BULIMIA NERVOSA MARKET SHARE BY REGION, 2018 (%)


FIGURE 9 NORTH AMERICA: BULIMIA NERVOSA MARKET SHARE, BY COUNTRY, 2018 (%)


FIGURE 10 EUROPE: BULIMIA NERVOSA MARKET SHARE, BY REGION, 2018 (%)


FIGURE 11 WESTERN EUROPE: BULIMIA NERVOSA MARKET SHARE, BY COUNTRY, 2018 (%)


FIGURE 12 ASIA-PACIFIC: BULIMIA NERVOSA MARKET SHARE, BY COUNTRY, 2018 (%)


FIGURE 13 MIDDLE EAST & AFRICA: BULIMIA NERVOSA MARKET SHARE, BY COUNTRY, 2018 (%)


FIGURE 14 GLOBAL BULIMIA NERVOSA MARKET: COMPANY SHARE ANALYSIS, 2018 (%)


FIGURE 15 ALLERGAN, INC..: KEY FINANCIALS


FIGURE 16 ALLERGAN, INC.: SEGMENTAL REVENUE


FIGURE 17 ALLERGAN, INC.: REGIONAL REVENUE


FIGURE 18 ELI LILLY AND COMPANY: KEY FINANCIALS


FIGURE 19 ELI LILLY AND COMPANY: SEGMENTAL REVENUE


FIGURE 20 ELI LILLY AND COMPANY: REGIONAL REVENUE


FIGURE 21 ASTRAZENECA: KEY FINANCIALS


FIGURE 22 ASTRAZENECA: SEGMENTAL REVENUE


FIGURE 23 ASTRAZENECA: REGIONAL REVENUE


FIGURE 24 BRISTOL-MYERS SQUIBB COMPANY: KEY FINANCIALS


FIGURE 25 BRISTOL-MYERS SQUIBB COMPANY: SEGMENTAL REVENUE


FIGURE 26 BRISTOL-MYERS SQUIBB COMPANY: REGIONAL REVENUE


FIGURE 27 GLAXOSMITHKLINE PLC: KEY FINANCIALS


FIGURE 28 GLAXOSMITHKLINE PLC: SEGMENTAL REVENUE


FIGURE 29 GLAXOSMITHKLINE PLC: REGIONAL REVENUE


FIGURE 30 PFIZER INC.: KEY FINANCIALS


FIGURE 31 PFIZER INC.: SEGMENTAL REVENUE


FIGURE 32 PFIZER INC.: REGIONAL REVENUE


FIGURE 33 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIALS


FIGURE 34 JOHNSON & JOHNSON SERVICES, INC.: SEGMENTAL REVENUE


FIGURE 35 JOHNSON & JOHNSON SERVICES, INC.: REGIONAL REVENUE


FIGURE 36 DR. REDDY’S LABORATORIES LIMITED: KEY FINANCIALS


FIGURE 37 DR. REDDY’S LABORATORIES LIMITED: SEGMENTAL REVENUE


FIGURE 38 DR. REDDY’S LABORATORIES LIMITED: REGIONAL REVENUE


FIGURE 39 LUPIN PHARMACEUTICALS, INC.: KEY FINANCIALS


FIGURE 40 LUPIN PHARMACEUTICALS, INC.: SEGMENTAL REVENUE


FIGURE 41 LUPIN PHARMACEUTICALS, INC.: REGIONAL REVENUE


FIGURE 42 AUROBINDO PHARMA: KEY FINANCIALS


FIGURE 43 AUROBINDO PHARMA: SEGMENTAL REVENUE


FIGURE 44 AUROBINDO PHARMA: REGIONAL REVENUE


FIGURE 45 ZYDUS CADILA: KEY FINANCIALS


FIGURE 46 ZYDUS CADILA: SEGMENTAL REVENUE


FIGURE 47 ZYDUS CADILA: REGIONAL REVENUE


FIGURE 48 APOTEX INC.: KEY FINANCIALS


FIGURE 49 APOTEX INC.: SEGMENTAL REVENUE


FIGURE 50 APOTEX INC.: REGIONAL REVENUE


FIGURE 51 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY FINANCIALS


FIGURE 52 TEVA PHARMACEUTICAL INDUSTRIES LTD: SEGMENTAL REVENUE


FIGURE 53 TEVA PHARMACEUTICAL INDUSTRIES LTD: REGIONAL REVENUE


FIGURE 54 SUN PHARMACEUTICAL INDUSTRIES LTD: KEY FINANCIALS


FIGURE 55 SUN PHARMACEUTICAL INDUSTRIES LTD: SEGMENTAL REVENUE


FIGURE 56 SUN PHARMACEUTICAL INDUSTRIES LTD: REGIONAL REVENUE